Travere Therapeutics ( (TVTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Travere Therapeutics’ stock has seen a downturn, even though the FDA’s cancellation of an advisory committee meeting for FILSPARI suggests confidence in its approval. Analysts have increased the price target, thanks to strong clinical data and fewer regulatory obstacles, boosting FILSPARI’s market potential. Nonetheless, mixed regulatory sentiment and ongoing financial challenges are still impacting the stock negatively.
More about Travere Therapeutics
YTD Price Performance: 43.96%
Average Trading Volume: 1,816,740
Technical Sentiment Signal: Buy
Current Market Cap: $2.43B
For further insights into TVTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.